美国安进狄诺塞麦多少钱一瓶？

RANKL inhibitor is a subcutaneous injection drug with better anti-bone metastasis effect than traditional bisphosphonates. It has been approved by the FDA and has been included in the NCCN guidelines. Bone metastasis is an unavoidable disease metastasis that occurs in the late stages of many cancer patients. In addition to multiple myeloma, the incidence of bone metastasis in breast cancer and prostate cancer is as high as more than 70%. The probability of bone metastasis in lung cancer is also among the highest. Common locations for bone metastases include: ribs, skull, hip, spine, thigh bone, and upper arm bone. Once bone metastasis occurs, it will lead to severe skeletal lesions, including bone pain, pathological fractures, spinal cord compression, hypercalcemia and other skeletal related events (SRE). The two common symptoms and consequences it brings often cause the patient's life and quality of life to decline rapidly. One is bone pain. 50% to 90% of patients with bone metastases will experience pain, of which 50% are severe pain and 30% are unbearable pain. The other is pathological fractures, especially when the bone metastasis is on load-bearing bones such as the spine and hip. A slight uneven force may cause fractures, compressing important nerves and spinal cord, or damaging internal organs, leading to paraplegia and bleeding and other malignant events. Denosumab is approved for the prevention of bone-related events in solid tumor bone metastases, but not for the prevention of bone-related events in patients with multiple myeloma. It is approved for use in adults or bone-mature adolescents with giant cell tumors of bone that are unresectable or where surgical resection may cause serious complications. It is approved for use in hypercalcemia of malignant tumors.

Amgen focuses on disease areas with huge medical needs that are far from being met, and uses its advanced experience in biopharmaceuticals to make outstanding contributions to improving human health and quality of life. Since its founding in 1980, Amgen has become one of the world's leading independent biotechnology companies, providing innovative drugs to millions of patients in more than 100 countries and regions around the world, and also has a number of promising drugs in development. According to the latest data collection, Amgen’s original drug specification of denosumab in the United States is 60mg/1ml tube/box, and the price is US$1,169.98. For domestic patients, China has not approved the drug for marketing, so they choose the original drug marketed in Turkey by Amgen of the United States. The specification is 125mg/1ml vial, and the price is equivalent to RMB 3,000.

Recommended hot articles: /newsDetail/92838.html